Cargando…
The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial
BACKGROUND: Mannitol, an osmotic diuretic, is proposed to be an oxygen radical scavenger. Mannitol is often used in renal transplantation to attenuate oxidative stress and thus to protect renal graft function. We tested the hypothesis that mannitol reduces overall oxidative stress during deceased do...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821012/ https://www.ncbi.nlm.nih.gov/pubmed/32966587 http://dx.doi.org/10.1111/aas.13713 |
_version_ | 1783639333466537984 |
---|---|
author | Reiterer, Christian Hu, Karin Sljivic, Samir Falkner von Sonnenburg, Markus Fleischmann, Edith Kabon, Barbara |
author_facet | Reiterer, Christian Hu, Karin Sljivic, Samir Falkner von Sonnenburg, Markus Fleischmann, Edith Kabon, Barbara |
author_sort | Reiterer, Christian |
collection | PubMed |
description | BACKGROUND: Mannitol, an osmotic diuretic, is proposed to be an oxygen radical scavenger. Mannitol is often used in renal transplantation to attenuate oxidative stress and thus to protect renal graft function. We tested the hypothesis that mannitol reduces overall oxidative stress during deceased donor renal transplantation. METHODS: We randomly assigned 34 patients undergoing deceased donor renal transplantation to receive a solution of mannitol or placebo shortly before graft reperfusion until the end of surgery. We evaluated oxidative stress by measuring the static oxidative‐reduction potential (sORP) and the capacity of the oxidative‐reduction potential (cORP). sORP and cORP were measured pre‐operatively, before and within 10 minutes after graft reperfusion, and post‐operatively. RESULTS: Seventeen patients were enrolled in the mannitol group and 17 patients were enrolled in the placebo group. Mannitol had no significant effect on sORP (148.5 mV [136.2; 160.2]) as compared to placebo (143.6 mV [135.8; 163.2], P = .99). There was also no significant difference in cORP between the mannitol (0.22 µC [0.16; 0.36]) and the placebo group (0.22 µC [0.17; 0.38], P = .76). CONCLUSION: Mannitol showed no systemic redox scavenging effects during deceased donor renal transplantation. To evaluate the direct effect of mannitol on the renal graft further studies are needed. Trial registration: ClinicalTrials.gov NCT02705573. |
format | Online Article Text |
id | pubmed-7821012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78210122021-01-26 The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial Reiterer, Christian Hu, Karin Sljivic, Samir Falkner von Sonnenburg, Markus Fleischmann, Edith Kabon, Barbara Acta Anaesthesiol Scand General Anaesthesia BACKGROUND: Mannitol, an osmotic diuretic, is proposed to be an oxygen radical scavenger. Mannitol is often used in renal transplantation to attenuate oxidative stress and thus to protect renal graft function. We tested the hypothesis that mannitol reduces overall oxidative stress during deceased donor renal transplantation. METHODS: We randomly assigned 34 patients undergoing deceased donor renal transplantation to receive a solution of mannitol or placebo shortly before graft reperfusion until the end of surgery. We evaluated oxidative stress by measuring the static oxidative‐reduction potential (sORP) and the capacity of the oxidative‐reduction potential (cORP). sORP and cORP were measured pre‐operatively, before and within 10 minutes after graft reperfusion, and post‐operatively. RESULTS: Seventeen patients were enrolled in the mannitol group and 17 patients were enrolled in the placebo group. Mannitol had no significant effect on sORP (148.5 mV [136.2; 160.2]) as compared to placebo (143.6 mV [135.8; 163.2], P = .99). There was also no significant difference in cORP between the mannitol (0.22 µC [0.16; 0.36]) and the placebo group (0.22 µC [0.17; 0.38], P = .76). CONCLUSION: Mannitol showed no systemic redox scavenging effects during deceased donor renal transplantation. To evaluate the direct effect of mannitol on the renal graft further studies are needed. Trial registration: ClinicalTrials.gov NCT02705573. John Wiley and Sons Inc. 2020-10-15 2021-02 /pmc/articles/PMC7821012/ /pubmed/32966587 http://dx.doi.org/10.1111/aas.13713 Text en © 2020 Medical University of Vienna. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | General Anaesthesia Reiterer, Christian Hu, Karin Sljivic, Samir Falkner von Sonnenburg, Markus Fleischmann, Edith Kabon, Barbara The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial |
title | The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial |
title_full | The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial |
title_fullStr | The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial |
title_full_unstemmed | The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial |
title_short | The effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—A randomized controlled trial |
title_sort | effect of mannitol on oxidation‐reduction potential in patients undergoing deceased donor renal transplantation—a randomized controlled trial |
topic | General Anaesthesia |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821012/ https://www.ncbi.nlm.nih.gov/pubmed/32966587 http://dx.doi.org/10.1111/aas.13713 |
work_keys_str_mv | AT reitererchristian theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT hukarin theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT sljivicsamir theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT falknervonsonnenburgmarkus theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT fleischmannedith theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT kabonbarbara theeffectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT reitererchristian effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT hukarin effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT sljivicsamir effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT falknervonsonnenburgmarkus effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT fleischmannedith effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial AT kabonbarbara effectofmannitolonoxidationreductionpotentialinpatientsundergoingdeceaseddonorrenaltransplantationarandomizedcontrolledtrial |